<DOC>
	<DOCNO>NCT01632696</DOCNO>
	<brief_summary>Tumor Imaging I-124 PGN65 Solid Tumors</brief_summary>
	<brief_title>Open-label , Single Arm , Tumor Imaging Dosimetry Study I-124 PGN650 Advanced Solid Tumors</brief_title>
	<detailed_description>Up 12 patient ( 6 men 6 woman ) enrol open-label , single-arm , tumor image dosimetry study I-124 PGN650 solid tumor . All eligible patient give write , informed consent meet inclusion criterion exclusion criterion , whose laboratory result within specified limit screen visit , enrol . All study subject receive single intravenous ( IV ) dose I-124 PGN650 . Study subject whole body PET/CT image three different timepoints patient PET/CT 0 60 minute injection I-124 PGN650 . Study subject assign either 3 5-hour 6 8-hour timepoint either 18 26 hour 42 52 hour post-injection timepoint . Tumor whole body radioactivity distribution measure .</detailed_description>
	<criteria>Inclusion Criteria 1 . Signed informed consent form . 2 . Male female , ≥ 18 year age . 3 . Histologically cytologically confirm solid tumor stage least one lesion ( primary , metastatic , recurrent ) ≥ 1.5 cm diameter document CT . If lesion locate lymph node , shortest diameter lymph node must ≥ 1.5 cm define RECIST 1.1 . ( Note : See Exclusion Criteria # 1 . ) 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . 5 . Adequate baseline hematological organ function , assess laboratory value prior study treatment follow : absolute neutrophil count ( ANC ) &gt; 1.0 x 109/L ; hemoglobin &gt; 7 g/dL ; serum creatinine &lt; 2 x institutional upper limit normal ( IULN ) ; aspartate transaminase ( AST ) &lt; 2.5 x IULN ; alanine transaminase ( ALT ) &lt; 2.5 x IULN ; ( liver metastases present , ALT AST &lt; 5 x IULN ) ; total bilirubin &lt; 1.5 x IULN . 6 . Women childbearing potential must agree use adequate contraception ( hormonal barrier method birth control , abstinence ) , duration study participation ( i.e. , dose day 1 study day 8 ) . Should woman become pregnant suspect pregnant participating study , must inform treat physician immediately . 7 . Patient must willing able undergo image study outline protocol . Exclusion Criteria 1 . Only measureable disease ( primary metastatic ) locate near thyroid gland , liver , kidney , urinary bladder . 2 . Medical condition ischemic heart lung disease may consider unacceptable risk . 3 . Females lactate pregnant . 4 . Persistent acute toxicity prior anticancer therapy . 5 . History hypersensitivity iodine . 6 . Known bladder outlet obstruction . 7 . Any condition would Investigator 's judgment prevents compliance requirement protocol . 8 . Patients known history autoimmune disease include limited : celiac disease , Crohn 's disease , dermatomyositis , Grave 's disease , systemic lupus erythematosus , myasthenia gravis , psoriasis , rheumatoid arthritis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Biologics</keyword>
	<keyword>F ( ab ' ) 2</keyword>
	<keyword>Positron-emission tomography ( PET )</keyword>
	<keyword>Phosphatidylserine ( PS )</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Tumor Imaging</keyword>
</DOC>